Biotest Aktiengesellschaft (BIO.DE)
EUR 41.4
(0.49%)
EUR 41.4
(0.49%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 143.5 Million EUR | 1101.54% |
| 2022 | -13 Million EUR | 75.05% |
| 2021 | -52.1 Million EUR | -294.7% |
| 2020 | -13.2 Million EUR | -103.08% |
| 2019 | -6.5 Million EUR | -161.32% |
| 2018 | 10.6 Million EUR | 213.98% |
| 2017 | -9.3 Million EUR | -114.55% |
| 2016 | 63.9 Million EUR | 189.0% |
| 2015 | -71.8 Million EUR | -234.46% |
| 2014 | 53.4 Million EUR | -0.74% |
| 2013 | 53.8 Million EUR | 20.48% |
| 2012 | 44.65 Million EUR | 7.44% |
| 2011 | 41.56 Million EUR | -3.11% |
| 2010 | 42.89 Million EUR | -30.22% |
| 2009 | 61.47 Million EUR | 10.49% |
| 2008 | 55.63 Million EUR | 44.47% |
| 2007 | 38.51 Million EUR | 22.7% |
| 2006 | 31.38 Million EUR | 24.14% |
| 2005 | 25.28 Million EUR | 35.73% |
| 2004 | 18.62 Million EUR | 143.41% |
| 2003 | 7.65 Million EUR | 12.78% |
| 2002 | 6.78 Million EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 52.4 Million EUR | 104.69% |
| 2024 Q2 | 15.5 Million EUR | -51.15% |
| 2023 Q3 | 133.3 Million EUR | 361.25% |
| 2023 Q1 | -9.1 Million EUR | -479.17% |
| 2023 Q2 | 28.9 Million EUR | 417.58% |
| 2023 Q4 | 25.6 Million EUR | -80.8% |
| 2023 FY | 130.19 Million EUR | 1101.54% |
| 2022 Q4 | 2.4 Million EUR | 124.24% |
| 2022 Q3 | -9.9 Million EUR | -135.71% |
| 2022 Q2 | -4.2 Million EUR | 16.0% |
| 2022 Q1 | -5 Million EUR | 86.07% |
| 2022 FY | -13 Million EUR | 75.05% |
| 2021 FY | -52.1 Million EUR | -294.7% |
| 2021 Q1 | -9.3 Million EUR | -243.08% |
| 2021 Q2 | 800 Thousand EUR | 108.6% |
| 2021 Q3 | -2.6 Million EUR | -425.0% |
| 2021 Q4 | -35.9 Million EUR | -1280.77% |
| 2020 FY | -13.2 Million EUR | -103.08% |
| 2020 Q1 | 1.4 Million EUR | -80.0% |
| 2020 Q2 | -700 Thousand EUR | -150.0% |
| 2020 Q3 | -8.5 Million EUR | -1114.29% |
| 2020 Q4 | 6.5 Million EUR | 176.47% |
| 2019 Q1 | -9.9 Million EUR | -280.0% |
| 2019 Q3 | -2.7 Million EUR | -161.36% |
| 2019 Q4 | 7 Million EUR | 359.26% |
| 2019 FY | -6.5 Million EUR | -161.32% |
| 2019 Q2 | 4.4 Million EUR | 144.44% |
| 2018 Q2 | 3.6 Million EUR | 220.0% |
| 2018 FY | 10.6 Million EUR | 213.98% |
| 2018 Q1 | -3 Million EUR | -146.88% |
| 2018 Q3 | 4.4 Million EUR | 22.22% |
| 2018 Q4 | 5.5 Million EUR | 25.0% |
| 2017 Q3 | 4.5 Million EUR | -4.26% |
| 2017 Q2 | 4.7 Million EUR | 118.88% |
| 2017 FY | -9.3 Million EUR | -114.55% |
| 2017 Q4 | 6.4 Million EUR | 42.22% |
| 2017 Q1 | -24.9 Million EUR | -165.87% |
| 2016 Q4 | 37.8 Million EUR | 378.48% |
| 2016 Q2 | 9.6 Million EUR | 11.63% |
| 2016 Q1 | 8.6 Million EUR | -15.69% |
| 2016 FY | 63.9 Million EUR | 189.0% |
| 2016 Q3 | 7.9 Million EUR | -17.71% |
| 2015 FY | -71.8 Million EUR | -234.46% |
| 2015 Q3 | -84.3 Million EUR | -3931.82% |
| 2015 Q4 | 10.2 Million EUR | 112.1% |
| 2015 Q2 | 2.2 Million EUR | 2100.0% |
| 2015 Q1 | 100 Thousand EUR | -99.45% |
| 2014 Q4 | 18.1 Million EUR | 105.68% |
| 2014 FY | 53.4 Million EUR | -0.74% |
| 2014 Q1 | 10.7 Million EUR | -23.02% |
| 2014 Q2 | 15.8 Million EUR | 47.66% |
| 2014 Q3 | 8.8 Million EUR | -44.3% |
| 2013 Q3 | 14 Million EUR | -0.71% |
| 2013 FY | 53.8 Million EUR | 20.48% |
| 2013 Q1 | 11.8 Million EUR | -0.45% |
| 2013 Q2 | 14.1 Million EUR | 19.49% |
| 2013 Q4 | 13.9 Million EUR | -0.71% |
| 2012 Q4 | 11.85 Million EUR | 19.73% |
| 2012 FY | 44.65 Million EUR | 7.44% |
| 2012 Q1 | 10.4 Million EUR | -9.25% |
| 2012 Q2 | 12.5 Million EUR | 20.19% |
| 2012 Q3 | 9.9 Million EUR | -20.8% |
| 2011 FY | 41.56 Million EUR | -3.11% |
| 2011 Q4 | 11.46 Million EUR | 13.47% |
| 2011 Q1 | 9.1 Million EUR | 18.27% |
| 2011 Q3 | 10.1 Million EUR | -7.34% |
| 2011 Q2 | 10.9 Million EUR | 19.78% |
| 2010 Q4 | 7.69 Million EUR | -33.1% |
| 2010 Q3 | 11.5 Million EUR | 0.88% |
| 2010 Q2 | 11.4 Million EUR | -7.32% |
| 2010 FY | 42.89 Million EUR | -30.22% |
| 2010 Q1 | 12.3 Million EUR | -13.22% |
| 2009 Q4 | 14.17 Million EUR | -11.97% |
| 2009 FY | 61.47 Million EUR | 10.49% |
| 2009 Q2 | 16.2 Million EUR | 8.0% |
| 2009 Q1 | 15 Million EUR | 0.0% |
| 2009 Q3 | 16.1 Million EUR | -0.62% |
| 2008 FY | 55.63 Million EUR | 44.47% |
| 2007 FY | 38.51 Million EUR | 22.7% |
| 2006 FY | 31.38 Million EUR | 24.14% |
| 2005 FY | 25.28 Million EUR | 35.73% |
| 2004 FY | 18.62 Million EUR | 143.41% |
| 2003 FY | 7.65 Million EUR | 12.78% |
| 2002 FY | 6.78 Million EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| BioNTech SE | 690.4 Million EUR | 79.215% |
| CureVac N.V. | -274.2 Million EUR | 152.333% |
| Biotest Aktiengesellschaft | 143.5 Million EUR | 0.0% |
| BRAIN Biotech AG | -6.71 Million EUR | 2237.007% |
| Formycon AG | -369 Thousand EUR | 38988.889% |
| Heidelberg Pharma AG | -21.2 Million EUR | 776.574% |
| Medigene AG | -16.14 Million EUR | 988.6% |